Rani Therapeutics Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
August 13, 2021 16:05 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq:RANI) (“Rani Therapeutics” or “Rani”), a clinical stage biotherapeutics company focused on advancing...
Rani Therapeutics Announces Pricing of Initial Public Offering
July 30, 2021 08:56 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., July 30, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”), a clinical stage biotherapeutics company focused on advancing technologies to...
Crinetics Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 13, 2019 16:11 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly
March 19, 2019 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 19, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
ProLynx extends lead in half-life extension platform technology – Shows primary deuterium kinetic isotope effects prolong drug release and polymer biodegradation in a drug delivery system
April 03, 2018 09:00 ET
|
ProLynx LLC
SAN FRANCISCO, April 03, 2018 (GLOBE NEWSWIRE) -- ProLynx announced today the publication of a paper demonstrating its leading capabilities to exploit primary deuterium kinetic isotope effects...
Chiasma Recognizes Acromegaly Awareness Day
November 01, 2017 08:50 ET
|
Chiasma, Inc.
WALTHAM, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...